Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 19/20 | 0.61 |
| ▸ | CTSK | P43235 | 16/20 | 0.61 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17708331 | 1.00 | CTSS (0.61) | CTSSCTSKCTSLCTSB | |
| SCHEMBL999757 | 1.00 | CTSS (0.61) | CTSSCTSKCTSLCTSB | |
| SCHEMBL999756 | 1.00 | CTSS (0.61) | CTSSCTSKCTSLCTSB | |
| SCHEMBL29524801 | 0.87 | CTSS (0.57) | CTSSCTSKCTSLCTSB | |
| SCHEMBL29063337 | 0.86 | CTSS (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL29046818 | 0.86 | CTSS (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL28752529 | 0.86 | CTSS (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL1645984 | 0.85 | CTSS (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL1645980 | 0.85 | CTSS (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL13318956 | 0.84 | CTSS (0.59) | CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132943-A1 | DECAHYDROQUINOLINES AS DNA POLYMERASE THETA INHIBITORS | BREAKPOINT THERAPEUTICS GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| CN-107709301-B | Pyrazole derivative or pharmacologically acceptable salt thereof | 橘生药品工业株式会社 | 2021-06-22 | — | — | CN | disclosed |
| CN-107709301-A | Pyrazole derivative or pharmacologically acceptable salt thereof | 橘生药品工业株式会社 | 2018-02-16 | — | — | CN | disclosed |
| WO-2017025849-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS | PFIZER INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| EP-2440558-B1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL (JP) | 2015-04-01 | — | — | EP | disclosed |
| US-8785429-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2014-07-22 | — | — | US | disclosed |
| US-20130184252-A1 | DIHYDROPYRROLONAPHTHYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-8420816-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| EP-1735332-B1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LAB (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20080113982-A1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | ZHAO CHEN | 2008-05-15 | — | — | US | disclosed |
| US-7345034-B2 | Azacyclosteroid histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1735332-A1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050245495-A1 | Azacyclosteroid histamine-3 receptor ligands | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| WO-2005100377-A1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050227953-A1 | Azacyclosteroid histamine-3 receptor ligands | ABBVIE INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184252-A1 | DIHYDROPYRROLONAPHTHYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | JAK2, JAK1, JAK3 | CTSS 3087/4885CTSK 2726/4885CTSL 2201/4885 |
| US-20050227953-A1 | Azacyclosteroid histamine-3 receptor ligands | HRH4, HRH3, HRH2 | CTSS 2225/4885CTSK 2157/4885CTSL 3887/4885 |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | JAK2, JAK1, JAK3 | CTSS 3125/4885CTSK 2813/4885CTSL 2176/4885 |
| US-20050245495-A1 | Azacyclosteroid histamine-3 receptor ligands | HRH4, HRH3, HRH2 | CTSS 2225/4885CTSK 2157/4885CTSL 3887/4885 |
| US-20080113982-A1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | HRH4, HRH3, HRH2 | CTSS 2225/4885CTSK 2157/4885CTSL 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.